drugset / Trial / NCT00050648
To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
RandomizedParallel-groupOpen-labelTreatment
Summary
This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab) and Cyclosporine in the treatment of psoriasis vulgaris. This is a three-armed study-Daclizumab alone, Cyclosporine alone, and the combination of both Daclizumab and Cyclosporine.
Timeline
- Start
- 1997-10
- Primary completion
- 2004-09
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | 2 mg/kg | Oral |
| Comparator | Daclizumab | Monoclonal antibody | 1 mg/kg | — |